Recent CDC data revealed an estimated 25,000 emergency room visits related to semaglutide weight loss drugs between 2022 and 2023, with the majority involving severe gastrointestinal complications requiring hospitalization
Women, on average, lose more weight than men on equivalent doses, possibly due to interactions between GLP-1 signaling and estrogen
The Pros and Cons of GLP Medications for Weight Optimization GLP medications have exploded on the health care scene this year
"Additionally, Blue Cross will end coverage of GLP-1 drugs for weight loss for large group fully insured members beginning January 1, 2025, or on a group's 2025 health coverage renewal date
Petersen Neuroendocrine Tumor Research Symposium (Watch the presentation beginning at 19:20 minutes into the session recording.) It doesnt provide final answers, but it offers important early clues about how GLP-1 drugs might interact with different types of NENs